Hereditary ovarian cancer in Ashkenazi Jews Journal Article

Authors: Robles-Díaz, L.; Goldfrank, D.; Kauff, N.; Robson, M.; Offit, K.
Article Title: Hereditary ovarian cancer in Ashkenazi Jews
Abstract: Ovarian cancer is the fourth leading cause of cancer deaths among American women. While women in both the Ashkenazi and non-Ashkenazi populations have an estimated 1.7% lifetime risk of acquiring malignancy, the proportion of hereditary ovarian cancer is much higher in the Ashkenazim. Most of this increased proportion of hereditary ovarian cancer risk is accounted for by inherited mutations in the BRCA1 and BRCA2 genes. In the Ashkenazi Jewish population, 29 to 41% of ovarian cancer is believed to be secondary to inheriting one of three founder mutations in BRCA1 and BRCA2, while only 10% of ovarian cancer is attributed to mutations of these genes in non-Ashkenazim. In the US population in general, it is estimated that between 1 out of 345 and 1 out of 1000 individuals carries a BRCA mutation, compared with approximately 1 in 40 individuals of Ashkenazi Jewish descent. The ovarian cancer risk up to age 70 associated with BRCA mutation carriers has been reported to be as high as 66% for BRCA1 and 27% for BRCA2 mutation carriers. Ovarian cancer in Ashkenazi kindreds has served as a model for the study of the histopathology of inherited ovarian cancers as well as for the study of risk reduction and screening among all women at inherited risk of ovarian cancer.
Keywords: adult; cancer chemotherapy; aged; middle aged; survival analysis; gene mutation; gene deletion; mutation; clinical trial; cancer risk; united states; antineoplastic agent; ovarian cancer; ovarian neoplasms; cancer susceptibility; genetic predisposition to disease; ovary cancer; breast cancer; incidence; neoplasm proteins; cancer screening; drug effect; brca1 protein; brca2 protein; heterozygote; cancer mortality; risk assessment; pedigree; genes, brca1; genes, brca2; familial cancer; age distribution; hormone; risk reduction; genetic predisposition; jews; brca1; hnpcc; brca2; oral contraceptive agent; jew; penetrance; brca mutation; ashkenazi; uterine tube ligation; humans; human; female; priority journal; article; genetic cancer predisposition
Journal Title: Familial Cancer
Volume: 3
Issue: 3-4
ISSN: 1389-9600
Publisher: Springer  
Date Published: 2004-01-01
Start Page: 259
End Page: 264
Language: English
DOI: 10.1007/s10689-004-9552-0
PROVIDER: scopus
PUBMED: 15516850
Notes: Fam. Cancer -- Cited By (since 1996):26 -- Export Date: 16 June 2014 -- CODEN: FCAAA -- Source: Scopus
Altmetric Score
MSK Authors
  1. Kenneth Offit
    519 Offit
  2. Mark E Robson
    368 Robson
  3. Noah Kauff
    122 Kauff